Practical consensus recommendations regarding the use of hormonal therapy in metastatic breast cancer

被引：3

作者：

Rajappa, Senthil ^{[1
]}

Bajpai, J. ^{[2
]}

Basade, M. ^{[3
]}

Ganvir, M. ^{[4
]}

Goswami, C. ^{[6
]}

Murali, A. ^{[7
]}

Rathi, A. K. ^{[7
]}

Kaushal, V. ^{[5
]}

Jain, S. ^{[8
]}

Parikh, Purvish M. ^{[9
]}

Aggarwal, S. ^{[4
]}

机构：

[1] IACH, Dept Med Oncol, Hyderabad, Telangana, India

[2] Tata Mem Hosp, Dept Med Oncol, Mumbai, Maharashtra, India

[3] Saifee Hosp, Dept Med Oncol, Mumbai, Maharashtra, India

[4] Sir Ganga Ram Hosp, Dept Med Oncol, New Delhi, India

[5] MAMC, Dept Radiat Oncol, New Delhi, India

[6] Apollo Gleneagles Hosp, Dept Radiat Oncol, Kolkata, W Bengal, India

[7] Sarvodaya Hosp, Dept Med Oncol, Faridabad, India

[8] RCC, Dept Radiat Oncol, Rohtak, Haryana, India

[9] Ludhiana Med Hosp, Dept Surg Oncol, Ludhinana, Punjab, India

来源：

SOUTH ASIAN JOURNAL OF CANCER | 2018年 / 7卷 / 02期

关键词：

Aromatase inhibitor; combination; endocrine therapy; ESR1; testing; evorolimus; exemestane; fulvestrant; palbociclib;

D O I：

10.4103/sajc.sajc_121_18

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic breast cancer (MBC) is cancer that has spread from the breast to another part of the body or has come back in another distant location. Treatment options for MBC depend on several factors. One of these factors is the levels of hormone receptors (HRs) in the tumor. Cancers with high levels of HRs, called HR-positive, use the hormones estrogen and progesterone to grow and spread. Hormonal therapy is a type of treatment specifically for HR-positive breast cancer. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at these practical consensus recommendations in regards with the use of hormonal therapy and the management of HR-positive MBC for the benefit of community oncologists.

引用

页码：137 / 141

页数：5

共 43 条

[1] Breast cancer care in India: The current scenario and the challenges for the future
Agarwal, Gaurav
Ramakant, Pooja
[J]. BREAST CARE, 2008, 3 (01) : 21 - 27
[2] [Anonymous], 2015, FDA APPR IB POST MEN
[3] [Anonymous], 2016, IBR PALB CAPS OR US
[4] Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor
Babiera, GV
Rao, R
Feng, L
Meric-Bernstam, F
Kuerer, HM
Singletary, SE
Hunt, KK
Ross, MI
Gwyn, KM
Feig, BW
Ames, FC
Hortobagyi, GN
[J]. ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (06) : 776 - 782
[5] Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial
Badwe, Rajendra
Hawaldar, Rohini
Nair, Nita
Kaushik, Rucha
Parmar, Vani
Siddique, Shabina
Budrukkar, Ashwini
Mittra, Indraneel
Gupta, Sudeep
[J]. LANCET ONCOLOGY, 2015, 16 (13) : 1380 - 1388
[6] The sequential use of endocrine treatment for advanced breast cancer: where are we?
Barrios, C.
Forbes, J. F.
Jonat, W.
Conte, P.
Gradishar, W.
Buzdar, A.
Gelmon, K.
Gnant, M.
Bonneterre, J.
Toi, M.
Hudis, C.
Robertson, J. F. R.
[J]. ANNALS OF ONCOLOGY, 2012, 23 (06) : 1378 - 1386
[7] Beaver JA, 2012, FUTURE ONCOL, V8, P651, DOI [10.2217/FON.12.49, 10.2217/fon.12.49]
[8] Bonneterre J, 2001, CANCER, V92, P2247, DOI 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO
[9] 2-Y
[10] 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F.
Costa, A.
Senkus, E.
Aapro, M.
Andre, F.
Barrios, C. H.
Bergh, J.
Bhattacharyya, G.
Biganzoli, L.
Cardoso, M. J.
Carey, L.
Corneliussen-James, D.
Curigliano, G.
Dieras, V.
El Saghir, N.
Eniu, A.
Fallowfield, L.
Fenech, D.
Francis, P.
Gelmon, K.
Gennari, A.
Harbeck, N.
Hudis, C.
Kaufman, B.
Krop, I.
Mayer, M.
Meijer, H.
Mertz, S.
Ohno, S.
Pagani, O.
Papadopoulos, E.
Peccatori, F.
Penault-Llorca, F.
Piccart, M. J.
Pierga, J. Y.
Rugo, H.
Shockney, L.
Sledge, G.
Swain, S.
Thomssen, C.
Tutt, A.
Vorobiof, D.
Xu, B.
Norton, L.
Winer, E.
[J]. ANNALS OF ONCOLOGY, 2017, 28 (01) : 16 - 33

← 1 2 3 4 5 →